Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Stroke. 2012 Jul;7(5):419-25. doi: 10.1111/j.1747-4949.2012.00783.x. Epub 2012 Mar 30.

Plasminogen activation and thrombolysis for ischemic stroke.

Author information

  • 1Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia. robert.medcalf@monash.edu

Abstract

The plasminogen-activating enzyme system has been exploited and harnessed for therapeutic thrombolysis for nearly three decades. Tissue-type plasminogen activator is still the only thrombolytic agent approved for patients with ischemic stroke. While tissue-type plasminogen activator-induced thrombolysis is proven to be of clear benefit in these patients if administered within 4·5 h poststroke onset, it is surprisingly underused in clinics despite international guidelines and improved acute stroke systems, a situation that requires urgent attention. While tissue-type plasminogen activator has also been shown to have unforeseen roles in the brain that have presented new challenges, tissue-type plasminogen activator and related fibrinolytic agents are currently being assessed over extended time frames. This review will focus on the therapeutic experience and controversies of tissue-type plasminogen activator. Furthermore, we will also provide an overview of recent and current trials assessing tissue-type plasminogen activator and related thrombolytic agents as well as novel approaches for the treatment of ischemic stroke.

© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk